ZV
Zevra Therapeutics, Inc.
ZVRA · NASDAQ
$11.61 -2.35% (-$0.28)
1M -2.19%
Market Cap $699.9M
P/E Ratio 12.01x
Div. Yield -
ROE 32.77%
Bulios Fair Price
$12.62
8.7% upside
Current Price
$11.61
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ZVRA is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
77 /100
Cheap EV/EBITDA 7.62x
P/S 5.14x
P/B 3.22x
Growth
100 /100
Growing Book val. growth 27.21%
Rev. growth 118.82%
FCF growth N/A
Profitability
100 /100
Strong Net margin 42.82%
Op. margin 28.71%
FCF margin 23.98%
Quality
78 /100
Excellent ROE 32.77%
ROA 19.25%
Asset turnover 0.45x
Debt
100 /100
Low Current ratio 5.17x
Int. coverage 12.54x
Net debt/EBITDA -1.97x
Stability
27 /100
Unstable Rev. volatility 182.47%
EPS volatility 133.00%
Profitable years 1
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ZVRA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Neil F. McFarlane
Employees
61
Headquarters
Boston
Upcoming events
04 NOV
Earnings
Upcoming earnings report